Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
Trevi Therapeutics (Nasdaq: TRVI) announced that data from their Phase 2a CANAL trial on Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) Congress 2024 in Vienna, Austria. The presentation, scheduled for September 8th, will focus on the correlation between changes in objective cough count and improvements in patient-reported outcomes with nalbuphine ER in IPF patients. Professor Jacky Smith, a renowned respiratory medicine expert, will deliver the oral presentation, highlighting the importance of patient-reported outcomes in clinical trials for chronic cough treatments, which remain a significant unmet need for IPF patients.
Trevi Therapeutics (Nasdaq: TRVI) ha annunciato che i dati della loro sperimentazione di Fase 2a CANAL su Haduvio™ (nalbupina ER orale) per la tosse cronica nella fibrosi polmonare idiopatica (IPF) saranno presentati al Congresso della Società Europea di Respirazione (ERS) 2024 a Vienna, Austria. La presentazione, programmata per l'8 settembre, si concentrerà sulla correlazione tra le variazioni nel conteggio obiettivo della tosse e i miglioramenti nei risultati riportati dai pazienti con nalbupina ER nei pazienti affetti da IPF. Il Professor Jacky Smith, un rinomato esperto di medicina respiratoria, terrà la presentazione orale, sottolineando l'importanza dei risultati riportati dai pazienti negli studi clinici per i trattamenti della tosse cronica, che rappresentano ancora un'importante esigenza insoddisfatta per i pazienti con IPF.
Trevi Therapeutics (Nasdaq: TRVI) anunció que los datos de su ensayo de Fase 2a CANAL sobre Haduvio™ (nalbufina ER oral) para la tos crónica en la fibrosis pulmonar idiopática (IPF) se presentarán en el Congreso de la Sociedad Europea de Respiración (ERS) 2024 en Viena, Austria. La presentación, programada para el 8 de septiembre, se centrará en la correlación entre los cambios en el conteo objetivo de la tos y las mejoras en los resultados autoinformados por los pacientes con nalbufina ER en pacientes con IPF. El Profesor Jacky Smith, un reconocido experto en medicina respiratoria, realizará la presentación oral, destacando la importancia de los resultados reportados por los pacientes en los ensayos clínicos para los tratamientos de la tos crónica, que siguen siendo una necesidad importante no satisfecha para los pacientes con IPF.
Trevi Therapeutics (Nasdaq: TRVI)는 만성 기침 및 특발성 폐섬유증(IPF) 치료를 위한 Haduvio™ (경구용 나르부핀 ER)의 2a 단계 CANAL 시험 데이터가 오스트리아 비엔나에서 개최되는 유럽 호흡기 학회(ERS) 2024에서 발표될 것이라고 발표했습니다. 9월 8일로 예정된 이 발표는 IPF 환자에서 나르부핀 ER의 객관적인 기침 수 변화와 환자가 보고한 결과 개선 간의 상관관계에 초점을 맞출 것입니다. 호흡기 의학 분야의 저명한 전문가인 Jacky Smith 교수는 만성 기침 치료를 위한 임상 시험에서 환자가 보고한 결과의 중요성을 강조하는 구두 발표를 진행할 것입니다. 이는 IPF 환자에게 여전히 중요한 미충족 요구 사항입니다.
Trevi Therapeutics (Nasdaq: TRVI) a annoncé que les données de leur essai de Phase 2a CANAL sur Haduvio™ (nalbuphine ER orale) pour la toux chronique dans la fibrose pulmonaire idiopathique (IPF) seront présentées au Congrès de la Société Européenne de Respiratoire (ERS) 2024 à Vienne, en Autriche. La présentation, prévue pour le 8 septembre, se concentrera sur la correlation entre les changements dans le compte objectif de la toux et les améliorations des résultats rapportés par les patients avec nalbuphine ER chez les patients atteints d'IPF. Le professeur Jacky Smith, un expert renommé en médecine respiratoire, fera la présentation orale, soulignant l'importance des résultats rapportés par les patients dans les essais cliniques pour les traitements de la toux chronique, qui restent un besoin non satisfait significatif pour les patients atteints d'IPF.
Trevi Therapeutics (Nasdaq: TRVI) hat angekündigt, dass die Daten aus ihrer Phase-2a-Studie CANAL zu Haduvio™ (orale Nalbuphin ER) für chronischen Husten bei idiopathischer Lungenfibrose (IPF) auf dem Kongress der Europäischen Gesellschaft für Atemwegserkrankungen (ERS) 2024 in Wien, Österreich, präsentiert werden. Die Präsentation, die für den 8. September geplant ist, wird sich auf die Zusammenhänge zwischen Veränderungen der objektiven Hustenanzahl und Verbesserungen der von den Patienten berichteten Ergebnisse bei IPF-Patienten mit Nalbuphin ER konzentrieren. Professor Jacky Smith, ein renommierter Experte für Atemwegserkrankungen, wird die mündliche Präsentation halten und die Bedeutung der von Patienten berichteten Ergebnisse in klinischen Studien zu Behandlungen des chronischen Hustens hervorheben, die weiterhin ein erhebliches unbefriedigtes Bedürfnis für IPF-Patienten darstellen.
- Phase 2a CANAL trial data to be presented at a major respiratory congress
- Focus on correlation between objective cough count and patient-reported outcomes
- Presentation by a respected expert in respiratory medicine
- None.
Professor Jacky Smith will present on the correlation between the change in objective cough count and improvement in patient-reported outcomes with nalbuphine ER in IPF patients
European Respiratory Society (ERS) Congress 2024
September 7-11, 2024,
Poster Session: Research studies in chronic cough
Session Date & Time: September 8, 8:00 a.m. – 9:30 a.m. CET
Location: PS-10
Abstract Accepted for Oral Presentation: Change in objective cough count correlates with improvement in patient-reported outcomes of cough in patients with idiopathic pulmonary fibrosis
Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of
Registration details: Registration - ERS Congress - official website (ersnet.org)
"I am delighted to discuss the correlation between the objective cough monitor and improvements in patient reported outcomes (PRO) with nalbuphine ER. PROs act as an important qualitative data point for clinical trials as they take into consideration the patient perspective. I am excited to present this data from the Phase 2a CANAL trial as treatments for chronic cough continue to be a high unmet need in IPF patients," said Prof. Smith.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is an extended-release (ER) dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough. Parenteral nalbuphine is not scheduled by the
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal benefit to patients. Chronic cough affects up to
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-oral-presentation-on-data-from-ph2a-canal-trial-at-the-european-respiratory-society-congress-2024-302238223.html
SOURCE Trevi Therapeutics, Inc.
FAQ
What is Trevi Therapeutics (TRVI) presenting at the ERS Congress 2024?
Who is presenting the TRVI Phase 2a CANAL trial data at ERS Congress 2024?
What is the focus of Trevi Therapeutics' (TRVI) presentation at ERS Congress 2024?
When and where is the ERS Congress 2024 where TRVI is presenting?
